Log in to save to my catalogue

Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in m...

Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in m...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2736462606

Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis

About this item

Full title

Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis

Publisher

England: BMJ Publishing Group Ltd

Journal title

Journal of neurology, neurosurgery and psychiatry, 2022-12, Vol.93 (12), p.1330-1337

Language

English

Formats

Publication information

Publisher

England: BMJ Publishing Group Ltd

More information

Scope and Contents

Contents

BackgroundTo compare the effectiveness and treatment persistence of ocrelizumab, cladribine and natalizumab in patients with relapsing–remitting multiple sclerosis switching from fingolimod.MethodsUsing data from MSBase registry, this multicentre cohort study included subjects who had used fingolimod for ≥6 months and then switched to ocrelizumab,...

Alternative Titles

Full title

Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_journals_2736462606

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2736462606

Other Identifiers

ISSN

0022-3050

E-ISSN

1468-330X

DOI

10.1136/jnnp-2022-330104

How to access this item